
Hangzhou Matridx Biotechnology Co., Ltd. (杰毅生物) is a high-tech enterprise based in Hangzhou, China, focused on innovative molecular diagnostics for infectious diseases. They leverage cutting-edge technologies like Next-Generation Sequencing (NGS) and CRISPR/Cas, holding nearly 100 patents. Matridx offers a comprehensive product line and service system for infectious disease molecular diagnosis, including automated sample preparation instruments and reagent solutions. A key product is the Q-mNGS™ quantitative metagenomic sequencing solution, noted as the first in China for automated detection, and the NGSmaster™ automated library preparation instrument which can complete the process in 120 minutes. They also provide the ResFirst respiratory pathogen detection kit. Matridx has strategic partnerships with Alibaba Cloud for AI applications in infectious diseases and collaborates with top clinical institutions in China. The company aims to be a leader in infectious disease diagnostics, driving the era of precision infectious medicine.

Hangzhou Matridx Biotechnology Co., Ltd. (杰毅生物) is a high-tech enterprise based in Hangzhou, China, focused on innovative molecular diagnostics for infectious diseases. They leverage cutting-edge technologies like Next-Generation Sequencing (NGS) and CRISPR/Cas, holding nearly 100 patents. Matridx offers a comprehensive product line and service system for infectious disease molecular diagnosis, including automated sample preparation instruments and reagent solutions. A key product is the Q-mNGS™ quantitative metagenomic sequencing solution, noted as the first in China for automated detection, and the NGSmaster™ automated library preparation instrument which can complete the process in 120 minutes. They also provide the ResFirst respiratory pathogen detection kit. Matridx has strategic partnerships with Alibaba Cloud for AI applications in infectious diseases and collaborates with top clinical institutions in China. The company aims to be a leader in infectious disease diagnostics, driving the era of precision infectious medicine.